New drug combo aims to wipe out rare blood cancer
NCT ID NCT00412594
Summary
This study is testing a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive a chemotherapy drug (cladribine) to kill cancer cells. Then, they receive an immunotherapy drug (rituximab) to help the immune system clean up any remaining cancer and potentially keep the disease from coming back. The goal is to see if this combination is more effective and provides longer-lasting results than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.